A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 11, 2008

Primary Completion Date

June 7, 2008

Study Completion Date

June 7, 2008

Conditions
AsthmaHealthy
Interventions
BIOLOGICAL

CAT-354 150 mg (intravenous)

A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.

BIOLOGICAL

CAT-354 150 mg (subcutaneous)

A single dose of CAT-354 150 mg injection subcutaneously on Day 0.

BIOLOGICAL

CAT-354 300 mg (subcutaneous)

A single dose of CAT-354 300 mg injection subcutaneously on Day 0.

Trial Locations (1)

68502

MDS Pharma Services (US) Inc., Lincoln

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00638989 - A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354 | Biotech Hunter | Biotech Hunter